Navigation Links
Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes

Randomized Comparator Study to Evaluate Efficacy of Commercially Available Hypomethylating Agents

WOODCLIFF LAKE, N.J., Dec. 2 /PRNewswire/ -- Eisai Corporation of North America today announced that it plans to initiate the first clinical trial evaluating the activity of Dacogen(R) (decitabine for injection) compared to Vidaza(R) (azacitidine) in adult patients with intermediate-1, intermediate-2 or high-risk myelodysplastic syndromes (MDS), a potentially life-threatening group of bone marrow diseases that limit the production of functional blood cells. The head-to-head trial will be conducted in the United States and will directly compare Dacogen(R) to Vidaza(R) with a primary endpoint of complete response rate (including marrow complete response).

"Previous to the introduction of the hypomethylating agents, supportive care was the only treatment option for patients living with MDS," said Dr. Hagop M. Kantarjian, chairman of the Leukemia Department and professor of medicine, University of Texas M.D. Anderson Cancer Center. "This study, for the first time, will provide physicians with important information to understand how these two agents compare when treating patients with MDS, who currently have a generally poor prognosis, with life expectancies shorter than those with lung cancer."

Study Design

This randomized, multi-center, open-label study will be conducted among 228 adult patients with intermediate-1, intermediate-2 and high-risk MDS. Patients will be randomized on a 1:1 ratio to either Dacogen(R) or Vidaza(R). Each treatment arm will be stratified by IPSS risk group and type of MDS (primary vs. secondary).

The study's primary objective is to compare the complete response rates, including bone marrow response rates, for Dacogen(R) versus Vidaza(R).

"Findings from this trial could help clarify the fundamental differences between Dacogen and Vidaza and ultimately help clinicians with treatment selection," said Dr. Anastasios Raptis, co-director, Myelodysplastic Syndrome Program, attending, Stem Cell Transplant Program and clinical assistant professor of medicine, University of Pittsburgh School of Medicine. "This study takes into account recent data that suggest that treatment of patients should continue for as long as they receive clinical benefit or until their disease progresses."

Eisai is committed to a clinical development program to optimize the utility of Dacogen(R) for patients with MDS. To advance the understanding of optimal treatment for MDS, hematological malignancies and other cancers, there are currently more than 30 ongoing trials with Dacogen(R) either as a single agent or in combination with other therapies.

About MDS

Myelodysplastic syndromes, or MDS, are a group of diseases of the bone marrow characterized by the production of poorly functioning and immature blood cells. People with MDS may experience a variety of symptoms and complications, including anemia, bleeding, infection, fatigue and weakness. Those patients with high-risk MDS may experience bone marrow failure, which may lead to death from bleeding and infection. Over time, MDS can progress to acute leukemia, or AML. The Aplastic Anemia and MDS International Foundation currently estimates that up to 30,000 new cases of MDS are diagnosed annually in the United States.

About Dacogen(R)

Dacogen(R) (decitabine for injection) was approved by the U.S. Food and Drug Administration on May 2, 2006, and is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups.

Dacogen(R) may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using Dacogen(R). Men should be advised not to father a child while receiving treatment with Dacogen(R) and for two months afterwards. The most commonly occurring adverse reactions with Dacogen(R) include neutropenia (90%), thrombocytopenia (89%), anemia (82%), pyrexia (53%), fatigue (48%), nausea (42%), cough (40%), petechiae (39%), constipation (35%), and diarrhea (34%).

Please visit for full prescribing information.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care.

Eisai Corporation of North America supports the activities of its operating companies in North America, which include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

SOURCE Eisai Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
7. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
8. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
9. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
10. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... ChiliPad , ... to maximize recovery through quality sleep. Tim DiFrancesco, training coach for the LA ... night’s sleep. ChiliPad precisely regulates the surface temperature of each side of the ...
(Date:11/30/2015)... ... 2015 , ... Using a combination of two blood sugar tests rather than ... to a new study by researchers at the School of Public Health at Georgia ... Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, the researchers ...
(Date:11/30/2015)... ... November 30, 2015 , ... Newly reviewed and approved “NJ Top Dentist”, ... Tufts School of Dental Medicine in 1935. His father graduated from NYU School ... in dentistry as well as their commitment and passion to the Practice of Dentistry. ...
(Date:11/30/2015)... New York, NY (PRWEB) , ... November 30, 2015 , ... ... New York Times,” will be released on December 1, 2015, to coincide with World ... book about the groundbreaking journalist who covered the AIDS epidemic as he was dying ...
(Date:11/30/2015)... ... November 30, 2015 , ... The American Society for Clinical ... of World AIDS Day 2015. On Nov. 30, ASCP shared its “Give a minute. ... World AIDS Day and the importance of getting tested for HIV. , ASCP has ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 North America ... expected to grow at a CAGR of 7.6% from 2015 to ... at USD 135.6 million in 2014, and is expected to grow ... According to the new Market Research Report "North America Cardiac ... End User (Hospitals, ambulatory care, others) - Analysis And Forecast To ...
(Date:11/30/2015)...  Kevin Smith has been appointed Chief Commercial ... in wireless monitoring of vital signs.  As CCO ... Mr. Smith will be responsible for the development ... will also directly oversee partnering with US hospitals ... SensiumVitals, the first early warning detection device to ...
(Date:11/30/2015)... SAN DIEGO , Nov. 30, 2015 ... ) today announced that the U.S. Food and Drug ... Application (NDA) for an extended release formulation of lorcaserin. ... a chronic weight management treatment in a once-daily dosing ... as an adjunct to a reduced-calorie diet and increased ...
Breaking Medicine Technology: